Business Responsibilty and Sustainability Report - 2025-26

To Dated 03.09.2026 BSE Limited National Stock Exchange of India Limited 25th Floor Exchange Plaza, C-1, Phiroze Jeejebhoy Towers Block - G Bandra Kurla Dalal Street, Mumbai 400 001 Complex Bandra (East) Mumbai – 400 051 BSE Code-531146 NSE Code: MEDICAMEQ Sub: Submission of Business Responsibility and Sustainability Report for the financial year 2025-26 Ref: Regulation 34(2)(f) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Dear Sir, Pursuant to provisions of Regulation 34(2)(f) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to SEBI Circular SEBI/HO/CFD/CMD-2/P/CIR/2021/562 dated May 10, 2021, kindly find enclosed herewith the Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The BRSR also forms part of Integrated Annual Report of the financial Year 2025-26, submitted to the Stock Exchanges. You are requested to take the same on record. Thanking You Yours truly, For Medicamen Biotech Limited Parul Choudhary Company Secretary ACS44157 Encl: As Above. ANNEXURE-D TO BOARD’S REPORT BUSINESS RESPONSIBILITY AND SUSTAINIBILITY REPORT SECTION A: GENERAL DISCLOSURES 1 Corporate Identity Number (CIN) of the Company L74899DL1993PLC056594 2 Name of the Company Medicamen Biotech Limited 3 Year of Incorporation 1993 4 Registered Office Address 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019 5 Corporate Address 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019 4 Website www.medicamen.com 5 Email ID cs@medicamen.com 6 Financial year reported 01 April 2025 to 31 March 2026 7 Sector(s) that the Company is engaged in NIC Code of product/service: 21001/21002 Manufacture of medicinal (industrial activity code-wise) substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts andesters; glycosides and vegetable alkaloids; chemically pure sugar etc. and Manufacture of allopathic pharmaceutical preparations. 8 List three key products/services that the MBL manufactures formulations of Oncology, Cardiovascular, Diabetic Company manufactures / provides (as in and Hypertension, Nutraceutical and Other Products. balance sheet) 9 Total number of locations where business There are 3 manufacturing facilities: activity is undertaken by the Company Bhiwadi Plant: SP-1192, A & B Phase-IV, Industrial Area, Distt Alwar, Bhiwadi 301019 (Rajasthan) Haridwar Plant: Unit-I: - Plot No 86 & 87, Sector 6A, IIE, Sidcul, Bhel, Ranipur, Haridwar-249403 Unit-II: - Plot No 84 & 85, Sector 6A, IIE, Sidcul, Bhel, Ranipur, Haridwar-249403 1. Number of international locations (Provide Nil details of major 5) 2. Number of national locations 3 10 Markets served by the Company - local / state / The Company, in addition to marketing its products domestically, also national / international markets its products globally over 35 countries. Around 80% of sales are generated from international markets. SECTION B: FINANCIAL DETAILS 1 Paid-up Capital (`) ` 13,56,28,150/- 2 Total Turnover (`) ` 178,84,58,167/- 3 Total Profit after Taxes (`) ` 9,40,86,731/- 4 Total spending on Corporate Social Responsibility During the Financial Year 2025-26, the Company was required to (CSR) as percentage of Profit after Tax (%) spend a statutory CSR amount of Rs. 31,33,024 in terms of Section 135 of the Companies Act, 2013. The Company incurred an amount of Rs. 25,20,000 towards various community and social welfare projects during the Financial Year. Accordingly, an unspent amount of Rs. 6,13,024.03 remained at the close of the Financial Year 2025-26. Since the said unspent amount did not relate to any Ongoing Project, the Company shall transfer the unspent CSR amount of Rs. 6,13,024.03 to the fund(s) specified in Schedule VII to the Companies Act, 2013, within the prescribed time limit and in accordance with the applicable provisions of Section 135 of the Companies Act, 2013. 5 List of activities in which the above expenditure (cid:120)(cid:3) Education has been incurred (cid:120)(cid:3) Health Annual Report 2025-26 33 Statutory Reports Corporate Overview Financial Statements ANNEXURE-D TO BOARD’S REPORT (CONTD.) SECTION C: OTHER DETAILS 1 Does the Company have any Subsidiary Yes, the Company have two subsidiaries named:- Company/ Companies? 1. OPAL Pharmaceuticals Pty Ltd (Wholly Owned Subsidiary) located at Australia 2. Medicamen Life Sciences Private Limited (holding 60% of total equity) 2 Do the Subsidiary Company / Companies The parent company undertakes majority of the BR initiatives participate in the BR initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s) 3 Do any other entity / entities (e.g. suppliers, Entities like suppliers, distributors do not participate in the Company BR distributors etc.) that the Company does initiatives in the reporting period. business with; participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity / entities? [Less than 30%, 30-60%, More than 60%] SECTION D: BR INFORMATION 1. A. Details of the Director / Directors responsible for implementation of the BR (Business Responsibility) policy / policies 1. DIN NUMBER 00317960 2. NAME Rahul Bishnoi 3. DESIGNATION Chairman B. Details of the BR head: 1. DIN NUMBER 00317960 2. NAME Rahul Bishnoi 3. DESIGNATION Chairman 4. TELEPHONE NUMBER 011-47589500 5. EMAIL ID info@medicamen.com I. PRODUCTS/SERVICES (cid:120)(cid:3) Details of business activities (accounting for 90% of the turnover): S. Description of Main Activity Description of Business Activity % of Turnover of No. the entity 1. Research & Development, Medicamen Biotech Limited is engaged in the 100 Manufacturing, Marketing, and manufacturing and marketing of pharmaceutical Distribution of Pharmaceutical formulations across various therapeutic segments. The Products Company manufactures tablets, capsules, dry syrups, oral liquids, ointments and other pharmaceutical dosage forms for domestic as well as international markets through its manufacturing facilities. The Company exports its products to more than 35 countries across Asia, Africa, Latin America and other international markets.. (cid:3) (cid:120)(cid:3) Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. Product/Service NIC Code % of total Turnover No. contributed 1. Pharmaceuticals products Division 1 96.43 Group 210 Class 2100 NIC 2008 21002 2. Pharmaceutical R&D/formulation NIC Code 2008 72100 3.42 development 34 Medicamen Biotech Limited ANNEXURE-D TO BOARD’S REPORT (CONTD.) II. OPERATIONS (cid:120)(cid:3) Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 3 1 4 International Nil Nil Nil (cid:120)(cid:3) Markets served by the entity: a. Number of locations Locations Number National (No. of States) PAN India (21 States) International (No. of Countries) More than 35 markets served across African countries, Brazil & Rest of World b. What is the contribution of exports as a percentage of the total turnover of the entity? c. A brief on types of customers: The Company’s customer base comprises domestic pharmaceutical distributors, stockists, institutional customers, government and semi-government healthcare organisations, hospitals, and private healthcare providers. In addition, the Company caters to international customers through exports to more than 30 countries, serving both regulated and semi-regulated markets. The Company is committed to delivering high- quality pharmaceutical products while maintaining long-term relationships with its customers through timely delivery, regulatory compliance and consistent product quality. III. EMPLOYEES (cid:120)(cid:3) Details [Showing first 8,000 characters — download PDF for full document]